

# Phase I trial code: RD 787.36057 (MTX325-101)

<b>Submission date</b> 05/03/2024	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
<b>Registration date</b> 06/03/2024	<b>Overall study status</b> Deferred	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
<b>Last Edited</b> 06/02/2025	<b>Condition category</b> Other	<input type="checkbox"/> Individual participant data <input type="checkbox"/> Record updated in last year

## Plain English summary of protocol

The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

## Contact information

### Type(s)

Scientific

### Contact name

Dr Suhail Nurbhai

### Contact details

Mission Therapeutics Ltd., The Glenn Berge Building, Babraham Research Campus  
Cambridge  
United Kingdom  
CB22 3FH  
+44 (0) 1223 867926  
snurbhai@missiontherapeutics.com

### Type(s)

Public

### Contact name

Ms Natalie Jones

### Contact details

Mission Therapeutics Ltd., The Glenn Berge Building, Babraham Research Campus  
Cambridge  
United Kingdom  
CB22 3FH  
+44 (0) 7462 135809  
njones@missiontherapeutics.com

## Type(s)

Principal investigator

## Contact name

Dr Annelize Koch

## Contact details

Simbec-Orion Clinical Pharmacology, Merthyr Tydfil Industrial Park, Cardiff Road  
Merthyr Tydfil  
United Kingdom  
CF48 4DR  
+44 (0)1443694313  
annelize.koch@simbecorion.com

## Additional identifiers

### Clinical Trials Information System (CTIS)

2024-517310-15

### Integrated Research Application System (IRAS)

1008552

### Protocol serial number

MTX325-101, IRAS 1008552

## Study information

### Scientific Title

Phase I trial code: RD 787.36057 (MTX325-101)

### Study objectives

The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

### Ethics approval required

Ethics approval required

### Ethics approval(s)

1. approved 21/11/2023, Wales Research Ethics Committee 2, Health and Care Research Wales (Castlebridge 4, 15-19 Cowbridge Road East, Cardiff, CF11 9AB, United Kingdom; +44 (0)2922 941119; Wales.REC2@wales.nhs.uk), ref: 23/WA/0258
2. approved 30/11/2023, MHRA (MHRA, 10 South Colonnade, Canary Wharf,, London, E14 4PU, United Kingdom; +44 (0) 20 3080 6000; info@mhra.gov.uk), ref: CTA 56125/0002/001-0001

### Study design

A five-part first-in-human trial in up to 158 healthy participants and patients with mild to moderate Parkinson's Disease

**Primary study design**

Interventional

**Study type(s)**

Safety

**Health condition(s) or problem(s) studied**

The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

**Interventions**

The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

**Intervention Type**

Drug

**Phase**

Phase I

**Drug/device/biological/vaccine name(s)**

The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

**Primary outcome(s)**

The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

**Key secondary outcome(s)**

The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

**Completion date**

09/05/2026

**Eligibility****Key inclusion criteria**

The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

**Participant type(s)**

Healthy volunteer, Patient

**Healthy volunteers allowed**

No

**Age group**

Mixed

**Lower age limit**

18 years

**Upper age limit**

75 years

**Sex**

All

**Key exclusion criteria**

The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

**Date of first enrolment**

06/02/2024

**Date of final enrolment**

14/11/2025

**Locations****Countries of recruitment**

United Kingdom

Wales

**Study participating centre****Simbec Research Limited**

Simbec House Merthyr Tydfil Industrial Park

Merthyr Tydfil Industrial Park

Pentrebach

Merthyr Tydfil

Mid Glamorgan

United Kingdom

CF48 4DR

**Sponsor information**

**Organisation**

Mission Therapeutics Ltd.

**Funder(s)****Funder type**

Industry

**Funder Name**

Mission Therapeutics Ltd.

**Results and Publications****Individual participant data (IPD) sharing plan**

The datasets generated and/or analysed during the current study are not expected to be made available because of their high commercial sensitivity and the negligible benefit to the public of publication of results of non-therapeutic clinical trials.

**IPD sharing plan summary**

Not expected to be made available